·Fintech Accounting
Medtech Accounting in Estonia: How Healthtech Startups Keep Books Through Years of R&D Before the First Euro of Revenue
A medtech startup can spend three to seven years in development, clinical validation and certification before the first sale. That inverts normal startup accounting: for years the books are all cost and grant money, and every reporting decision, from capitalising CE-marking costs to structuring Horizon Europe cost centres, shapes what investors see. Estonia is a strong base for this: 0% corporate tax on retained profit means nothing leaks to tax while you build. This guide covers the accounting questions we work through with seed and VC-funded medtech and healthtech clients.
What makes medtech accounting different in Estonia?
Medtech accounting is different because the business spends years as pure cost centre before it earns anything. A software startup can show revenue in month three; a medical device or clinical healthtech company first has to get through prototyping, clinical evidence, CE marking under the EU Medical Device Regulation (MDR) and often a notified-body queue. For the whole of that period the ledger is development salaries, lab and certification fees, and grant income, and the only numbers investors can judge you on are how cleanly those costs are structured and how honestly burn is reported.
Estonia is an unusually good jurisdiction to do those years in. Corporate income tax of 22% applies only to distributed profits; retained and reinvested profit is taxed at 0%, so every euro raised or earned that stays in the company funds R&D untaxed until distribution. An OÜ needs €1 of share capital and one annual report to RIK, and e-Residency lets a foreign founder or a distributed clinical team run the entity remotely. The tax regime rewards exactly what a medtech company does for its first five years: keep everything inside and build.
How does the 0% tax on retained profit change a long R&D runway?
In a classical tax system, a company that becomes profitable pays corporate tax annually, whether or not the owners take anything out. Estonia defers the entire 22% until profit is actually distributed as dividends. For a medtech startup this has a compounding effect: revenue from a first regulated market, licensing income or milestone payments from a partner can be recycled into the next clinical study with zero tax leakage. The tax bill only arrives when shareholders decide to take money out, which in a venture-backed medtech is typically at exit, not during the build.
The practical accounting consequence is that the balance sheet, not the tax return, becomes the document that matters. Investors and grant bodies read accumulated development spend, grant liabilities and cash position from the annual report filed at RIK. We close medtech books monthly so that the year-end report is a formality rather than an archaeology project, and so the burn number the board sees in month eleven matches what the statutory report will say in month fourteen.
Should you capitalise clinical and certification costs like CE marking and MDR?
This is the single most consequential bookkeeping decision a medtech founder makes. Development costs, including clinical validation, technical documentation and CE-marking or MDR certification fees, can be capitalised as an intangible asset when the project is technically feasible and expected to generate future benefit; otherwise they are expensed as incurred. Capitalising makes the P&L look dramatically better and builds an asset on the balance sheet; expensing is more conservative and keeps the burn number honest.
There is no universally right answer, but there is a universally wrong one: deciding retroactively, in the week before a funding round, to reclassify two years of costs. Sophisticated medtech investors will re-derive true burn either way, and an auditor will challenge capitalisation that lacks a documented feasibility assessment. We help clients set the policy early, document the trigger point (typically design freeze or the start of the conformity-assessment route), and apply it consistently so the data room tells one story instead of three.
How do you account for EAS, Enterprise Estonia and Horizon Europe grants?
Grant money carries the most audit risk of anything in medtech books. EAS and Enterprise Estonia development grants, Horizon Europe consortium funding and national health-innovation programmes each define eligible costs, co-financing rates and reporting periods, and each can claw money back years later if the paper trail fails. The accounting baseline: recognise grant income as the related eligible costs are incurred (not when the advance lands), run every project in its own cost centre, and keep timesheets for every person whose salary is charged to the grant.
Horizon Europe adds its own layer: personnel costs calculated on documented productive hours, depreciation rules for equipment used across projects, and consortium reporting where your numbers must reconcile with a coordinator abroad. Setting this structure up after the first reporting deadline is painful; setting it up when the grant agreement is signed is routine. It is one of the most common projects we run for healthtech clients in their first funded year.
When is reimbursement revenue actually revenue?
Healthtech revenue often arrives through payers rather than customers: national health insurance funds, hospital procurement, or per-procedure reimbursement codes. The accounting question is when a claim becomes revenue, because reimbursement can be submitted in one quarter, adjudicated in the next and partially rejected in a third. Recognising the full claimed amount on submission overstates revenue; a documented expected-value or historical-acceptance-rate approach keeps the books defensible.
The same discipline applies to pilots with hospitals and clinics. A paid pilot with an evaluation clause may be revenue, a refundable deposit or a conditional milestone may not be yet. For a seed-stage healthtech reporting traction to investors, the difference between signed pilot value and recognisable revenue needs to be explicit in the monthly pack, because diligence will find it anyway.
What burn reporting do medtech investors expect at seed and beyond?
Medtech rounds are larger and further apart than SaaS rounds, so investors scrutinise burn harder. The expected pack: monthly gross and net burn split between regulatory, clinical, engineering and G&A; runway against the regulatory milestone plan rather than a flat average; grant income shown separately from commercial revenue so traction is not flattered; and clean TSD payroll filings covering salaries and any ESOP grants. A data room where every burn number ties to the ledger closes rounds faster.
TechAccounting builds and runs that layer for tech companies in Estonia. For medtech and healthtech OÜs we handle monthly closes, capitalisation policy, EAS and Horizon Europe cost-centre accounting, payroll with ESOP and TSD mechanics, and investor reporting, from e-Resident founders pre-revenue to VC-funded teams heading into a Series A. Accounting packages start at €499 per month, compliance-heavy setups at €1,500, and one-off consultations at €150 per hour when you need the capitalisation question answered before your round.